Therapy that inhibits VEGF is an effective therapeutic modality targeting the underlying pathogenesis of macular edema in RVO and anti-VEGF intravitreal therapy has become the standard of care for treating this disease [7]. This evidence concerns the gene VEGFA and macular retinal edema.